State Street
AVIR icon

State Street’s Atea Pharmaceuticals AVIR Stock Holding History

State Street’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.68M Sell
1,652,399
-42,236
-2% -$210K ﹤0.01% 2823
2026
Q1 		$9.12M Sell
1,694,635
-89,832
-5% -$413K ﹤0.01% 2664
2025
Q4 		$6.37M Buy
1,784,467
+491
+0% +$1.56K ﹤0.01% 2875
2025
Q3 		$5.17M Buy
1,783,976
+7,575
+0.4% +$25.9K ﹤0.01% 2980
2025
Q2 		$6.4M Buy
1,776,401
+5,713
+0.3% +$17K ﹤0.01% 2829
2025
Q1 		$5.29M Sell
1,770,688
-15,390
-0.9% -$48K ﹤0.01% 2856
2024
Q4 		$5.98M Buy
1,786,078
+52,592
+3% +$175K ﹤0.01% 2883
2024
Q3 		$5.81M Buy
1,733,486
+11,566
+0.7% +$41.9K ﹤0.01% 2896
2024
Q2 		$5.7M Buy
1,721,920
+43,537
+3% +$162K ﹤0.01% 2861
2024
Q1 		$6.78M Buy
1,678,383
+48,346
+3% +$189K ﹤0.01% 2793
2023
Q4 		$4.97M Buy
1,630,037
+123,800
+8% +$375K ﹤0.01% 2947
2023
Q3 		$4.52M Sell
1,506,237
-27,051
-2% -$92K ﹤0.01% 2967
2023
Q2 		$5.73M Sell
1,533,288
-330,049
-18% -$1.24M ﹤0.01% 2931
2023
Q1 		$6.24M Sell
1,863,337
-74,393
-4% -$302K ﹤0.01% 2906
2022
Q4 		$9.32M Buy
1,937,730
+42,994
+2% +$217K ﹤0.01% 2738
2022
Q3 		$10.8M Buy
1,894,736
+91,368
+5% +$699K ﹤0.01% 2663
2022
Q2 		$12.8M Sell
1,803,368
-68,706
-4% -$469K ﹤0.01% 2550
2022
Q1 		$13.5M Sell
1,872,074
-453,379
-19% -$3.08M ﹤0.01% 2654
2021
Q4 		$20.8M Buy
2,325,453
+1,222,601
+111% +$19.1M ﹤0.01% 2454
2021
Q3 		$38.7M Buy
1,102,852
+141,085
+15% +$3.91M ﹤0.01% 1992
2021
Q2 		$20.7M Buy
961,767
+677,244
+238% +$20.3M ﹤0.01% 2487
2021
Q1 		$17.6M Buy
284,523
+61,849
+28% +$4.18M ﹤0.01% 2444
2020
Q4 		$9.3M Buy
+222,674
New +$7.18M ﹤0.01% 2671

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street's AVIR Position: Q2 2026 in Review

State Street reduced its Atea Pharmaceuticals (AVIR) stake by 2.5% in Q2 2026, selling an estimated $210K and leaving 1,652,399 shares worth $7.68M. The position accounts for ﹤0.01% of the portfolio, ranked #2823.

State Street first reported a position in AVIR in Q4 2020 and has held it in 23 quarters since. The position peaked at $38.7M in Q3 2021. 125 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

  • State Street held 1,652,399 shares of Atea Pharmaceuticals worth $7.68M as of Q2 2026.
  • State Street sold 42,236 Atea Pharmaceuticals shares in Q2 2026, an estimated $210K.
  • Atea Pharmaceuticals made up ﹤0.01% of State Street's portfolio in Q2 2026, its #2823 holding.
  • State Street first reported a position in Atea Pharmaceuticals in Q4 2020 and has held it in 23 quarters since.
  • State Street's Atea Pharmaceuticals position peaked at $38.7M in Q3 2021.
  • 125 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.